T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$784M |
| 2 |
Danaher
DHR
|
+$764M |
| 3 |
Intuit
INTU
|
+$679M |
| 4 |
PTC
PTC
|
+$559M |
| 5 |
Avantor
AVTR
|
+$447M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CrowdStrike
CRWD
|
+$766M |
| 2 |
Spotify
SPOT
|
+$730M |
| 3 |
KKR & Co
KKR
|
+$587M |
| 4 |
Goldman Sachs
GS
|
+$531M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$515M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.38% |
| 2 | Healthcare | 20.33% |
| 3 | Industrials | 12.32% |
| 4 | Consumer Discretionary | 11.88% |
| 5 | Financials | 10.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PVBC
551
DELISTED
Provident Bancorp
PVBC
| $8.39M | 0.01% |
823,253
-604,197
| -42% | -$5.57M |
|
|
GRFS
552
Grifois
GRFS
$5.42B
| $8.21M | 0.01% |
1,303,596
-714,607
| -35% | -$4.97M |
|
|
553
Goldman Sachs
GS
$306B
| $8M | 0.01% |
17,687
-1,210,191
| -99% | -$531M |
|
554
Douglas Dynamics
PLOW
$977M
| $7.94M | 0.01% |
339,222
-543
| -0.2% | -$12.9K |
|
555
Keurig Dr Pepper
KDP
$41.8B
| $7.61M | ﹤0.01% |
227,672
+95,400
| +72% | +$3.17M |
|
|
CNTA
556
DELISTED
Centessa Pharmaceuticals
CNTA
| $7.53M | ﹤0.01% |
+833,993
| New | +$7.91M |
|
557
Madrigal Pharmaceuticals
MDGL
$12.2B
| $7.18M | ﹤0.01% |
25,644
-17,342
| -40% | -$4.13M |
|
558
BridgeBio Pharma
BBIO
$16.2B
| $7M | ﹤0.01% |
276,369
-1,168,748
| -81% | -$32M |
|
559
Nike
NKE
$60.6B
| $6.94M | ﹤0.01% |
92,080
+36,013
| +64% | +$3.35M |
|
560
SLB Ltd
SLB
$77.5B
| $6.68M | ﹤0.01% |
141,562
+79,953
| +130% | +$3.86M |
|
561
Morgan Stanley
MS
$346B
| $6.67M | ﹤0.01% |
68,631
-5,146,784
| -99% | -$490M |
|
562
KLA
KLAC
$276B
| $6.48M | ﹤0.01% |
78,600
-5,140,210
| -98% | -$380M |
|
563
Lockheed Martin
LMT
$139B
| $6.4M | ﹤0.01% |
13,701
+3,390
| +33% | +$1.57M |
|
564
Winnebago Industries
WGO
$924M
| $6.36M | ﹤0.01% |
+117,314
| New | +$7.23M |
|
565
Syndax Pharmaceuticals
SNDX
$1.75B
| $5.83M | ﹤0.01% |
283,827
-2,175,408
| -88% | -$45.5M |
|
566
Stryker
SYK
$131B
| $5.55M | ﹤0.01% |
16,321
-683
| -4% | -$231K |
|
567
S&P Global
SPGI
$122B
| $5.54M | ﹤0.01% |
12,413
+1,440
| +13% | +$618K |
|
568
CSX Corp
CSX
$93.5B
| $5.44M | ﹤0.01% |
162,531
+18,937
| +13% | +$643K |
|
569
Marriott International
MAR
$92.4B
| $5.43M | ﹤0.01% |
22,465
+2,800
| +14% | +$672K |
|
570
PNC Financial Services
PNC
$102B
| $5.43M | ﹤0.01% |
34,928
-3,216,229
| -99% | -$498M |
|
571
Zentalis Pharmaceuticals
ZNTL
$310M
| $5.42M | ﹤0.01% |
1,325,491
-1,993,595
| -60% | -$22.3M |
|
572
Zoetis
ZTS
$30.5B
| $5.39M | ﹤0.01% |
31,076
-14,968
| -33% | -$2.49M |
|
|
ANSS
573
DELISTED
Ansys
ANSS
| $5.01M | ﹤0.01% |
+15,576
| New | +$5.1M |
|
574
Nkarta
NKTX
$170M
| $4.78M | ﹤0.01% |
808,566
-546,755
| -40% | -$3.87M |
|
575
Ascendis Pharma A/S
ASND
$16.1B
| $4.17M | ﹤0.01% |
30,564
-2,538,339
| -99% | -$345M |
|
Similar funds
T. Rowe Price Investment Management's Q2 2024 Portfolio in Review
As of Q2 2024, T. Rowe Price Investment Management held 668 positions worth $158B, down 3.1% from $163B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
T. Rowe Price Investment Management's Q2 2024 filing shows 48 new, 292 increased, 275 reduced and 48 closed positions. Its largest new stake was Broadcom: 5,594,890 shares worth $898M. The largest sale was CrowdStrike, an estimated $766M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Healthcare and Industrials.
- T. Rowe Price Investment Management's largest Q2 2024 buy was Broadcom: 5,594,890 shares worth $898M.
- T. Rowe Price Investment Management added most to Danaher in Q2 2024, an estimated $764M increase.
- T. Rowe Price Investment Management's biggest Q2 2024 reduction was CrowdStrike, cutting an estimated $766M.
- T. Rowe Price Investment Management fully exited CATALENT, INC. in Q2 2024, selling an estimated $231M.
- T. Rowe Price Investment Management's ten largest holdings make up 17% of its $158B portfolio in Q2 2024.
- T. Rowe Price Investment Management opened 48 new positions and closed 48 in Q2 2024.
- T. Rowe Price Investment Management's portfolio value fell 3.1% quarter-over-quarter to $158B.
Based on T. Rowe Price Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.